X
[{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of Positive Results of the AE37 Phase IIb Breast Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"NuGenerex","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"NuGenerex Immuno-Oncology Closes $50 Million Financing Facility","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NuGenerex Immuno-Oncology Publishes Review Article on Cancer Vaccines Highlighting AE37 (Ii-Key-HER2) Immunotherapeutic Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for AE37 Peptide
Filters
Companies By Therapeutic Area
Details:
The paper describes why the Phase IIb clinical trial of AE37 in breast cancer demonstrated a statistically significant clinical benefit for certain subgroups of patients in the trial while failing to meet the primary endpoint in the entire intent-to-treat study population.
Lead Product(s):
AE37 Peptide ,Sargramostim
Therapeutic Area: Oncology
Product Name: AE37
Highest Development Status: Phase II
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 13, 2020
Details:
NuGenerex Immuno-Oncology is developing immunotherapeutic Ii-Key peptide vaccines for cancer and infectious diseases.
Lead Product(s):
AE37 Peptide ,Pembrolizumab
Therapeutic Area: Oncology
Product Name: AE37
Highest Development Status: Phase II
Product Type: Peptide
Partner/Sponsor/Collaborator:
Undisclosed
Deal Size: $50.0 million
Upfront Cash: Undisclosed
Deal Type: Financing
July 15, 2020
Details:
The presentation revealed AE37 Ii-Key peptide vaccine is safe and associated with DFS in sub-sets of breast cancer survivors after 10-year follow-up
.
Lead Product(s):
AE37 Peptide ,Sargramostim
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 28, 2020